Evidence map›Paper›PMID 35382635›Full record

ArticleTechnology in cancer research & treatment

Rationale for Tailoring an Alternative Oncology Trial Using a Novel Gallium-Based Nanocomplex: Mechanistic Insights and Preclinical Challenges.

Nihal Mostafa, Ahmed Salem, Somaya Z Mansour, Sawsan M El-Sonbaty, Fatma S M Moawed, Eman I Kandil

Open access · goldAbstract read
In one paragraph

Article in Technology in cancer research & treatment. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Bioinorganic Modulators of Ferroptosis: A Review of Recent Findings.International journal of molecular sciences · 2023
    Review
  5. CharacterizingJournal of oncology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Nihal MostafaDepartment of Biochemistry, Faculty of Science, 247928Ain Shams University, Cairo, Egypt.ORCID 0000-0002-9180-0630
Ahmed SalemDepartment of Biochemistry, Faculty of Science, 247928Ain Shams University, Cairo, Egypt.
Somaya Z MansourRadiation Biology, National Center for Radiation Research and Technology (NCRRT), 68892Atomic Energy Authority (AEA), Cairo, Egypt.
Sawsan M El-SonbatyRadiation Microbiology, National Center for Radiation Research and Technology (NCRRT), 68892Atomic Energy Authority (AEA), Cairo, Egypt.
Fatma S M MoawedHealth Radiation Research, National Center for Radiation Research and Technology (NCRRT), 68892Atomic Energy Authority (AEA), Cairo, Egypt.
Eman I KandilDepartment of Biochemistry, Faculty of Science, 247928Ain Shams University, Cairo, Egypt.
Ain Shams University · EGEgyptian Atomic Energy Authority · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic AgentsGalliumLiver NeoplasmsNanoparticlesHumansNanotechnologyAntineoplastic AgentsGalliumcisplatin (CDDP)gallic acid (GA)gallium (Ga)green nanotechnologyhepatocarcinogenesis

Identifiers

PMID35382635
PMCPMC8990695
OpenAlexW4223589824

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.